Immutep Limited

What they do

Immutep is a biotechnology company focused on developing LAG-3 immunotherapies for cancer. Its operations primarily involve research and development activities, including clinical trials, with expenditures going to third-party vendors for contract research and manufacturing. The company also maintains a subsidiary in France and has a corporate income tax rate of 10% applicable to its French operations.

Revenue drivers

• Research and development — The company does not generate product revenue; its main cost and focus is R&D. R&D expenses include third-party contract research and manufacturing activities, which are the primary use of cash.

Recent performance

As of June 30, 2025, the company reported no product revenue, consistent with its clinical-stage status. R&D expenses are a significant driver of its cash burn, with prepayments made to clinical trial organizations. The weighted average share price on exercise during fiscal 2025 was $0.332. The company also recognized share-based expenses related to performance rights, with vesting conditions tied to service and corporate KPIs.

Strategy

The company's strategy is to advance its immunotherapy pipeline through clinical trials. It invests in external R&D services and manages its cash through offerings such as convertible notes and warrants. Management focuses on meeting development milestones and managing liquidity through capital raises and cost control.

Risks

• Clinical trial failure — As a clinical-stage company, failure to demonstrate safety and efficacy in trials would significantly impair its prospects.
• Cash burn — The company has no revenue and relies on external financing, so continued cash burn may require dilutive capital raises.
• Regulatory uncertainty — Delays in regulatory approvals in key markets, including the U.S. and Europe, could postpone product commercialization.
• Reliance on third-party vendors — R&D is outsourced to contract research and manufacturing organizations, and any disruption could delay trials.

Outlook

Management indicates ongoing clinical development activities, with prepayments to trial organizations suggesting continuity in trial execution. The company expects to continue incurring R&D expenses and may need additional funding to support operations. No specific near-term catalyst or revenue timeline is provided.